98 related articles for article (PubMed ID: 22169598)
1. TLR9 expression is associated with prognosis in patients with glioblastoma multiforme.
Leng L; Jiang T; Zhang Y
J Clin Neurosci; 2012 Jan; 19(1):75-80. PubMed ID: 22169598
[TBL] [Abstract][Full Text] [Related]
2. TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients.
Wang C; Cao S; Yan Y; Ying Q; Jiang T; Xu K; Wu A
BMC Cancer; 2010 Aug; 10():415. PubMed ID: 20696081
[TBL] [Abstract][Full Text] [Related]
3. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity.
Merrell MA; Ilvesaro JM; Lehtonen N; Sorsa T; Gehrs B; Rosenthal E; Chen D; Shackley B; Harris KW; Selander KS
Mol Cancer Res; 2006 Jul; 4(7):437-47. PubMed ID: 16849519
[TBL] [Abstract][Full Text] [Related]
4. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro.
Ilvesaro JM; Merrell MA; Swain TM; Davidson J; Zayzafoon M; Harris KW; Selander KS
Prostate; 2007 May; 67(7):774-81. PubMed ID: 17373717
[TBL] [Abstract][Full Text] [Related]
5. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors.
El Andaloussi A; Sonabend AM; Han Y; Lesniak MS
Glia; 2006 Nov; 54(6):526-35. PubMed ID: 16906541
[TBL] [Abstract][Full Text] [Related]
6. Human lung cancer cells express functionally active Toll-like receptor 9.
Droemann D; Albrecht D; Gerdes J; Ulmer AJ; Branscheid D; Vollmer E; Dalhoff K; Zabel P; Goldmann T
Respir Res; 2005 Jan; 6(1):1. PubMed ID: 15631627
[TBL] [Abstract][Full Text] [Related]
7. Differential contribution of osteoclast- and osteoblast-lineage cells to CpG-oligodeoxynucleotide (CpG-ODN) modulation of osteoclastogenesis.
Amcheslavsky A; Hemmi H; Akira S; Bar-Shavit Z
J Bone Miner Res; 2005 Sep; 20(9):1692-9. PubMed ID: 16059640
[TBL] [Abstract][Full Text] [Related]
8. Expression of TLR9 within human glioblastoma.
Meng Y; Kujas M; Marie Y; Paris S; Thillet J; Delattre JY; Carpentier AF
J Neurooncol; 2008 May; 88(1):19-25. PubMed ID: 18253698
[TBL] [Abstract][Full Text] [Related]
9. CpG-oligodeoxynucleotide inhibits Smad-dependent bone morphogenetic protein signaling: effects on myeloma cell apoptosis and in vitro osteoblastogenesis.
Nørgaard NN; Holien T; Jönsson S; Hella H; Espevik T; Sundan A; Standal T
J Immunol; 2010 Sep; 185(6):3131-9. PubMed ID: 20702733
[TBL] [Abstract][Full Text] [Related]
10. c-Met expression is associated with time to recurrence in patients with glioblastoma multiforme.
Liu W; Fu Y; Xu S; Ding F; Zhao G; Zhang K; Du C; Pang B; Pang Q
J Clin Neurosci; 2011 Jan; 18(1):119-21. PubMed ID: 20832323
[TBL] [Abstract][Full Text] [Related]
11. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.
Choe G; Park JK; Jouben-Steele L; Kremen TJ; Liau LM; Vinters HV; Cloughesy TF; Mischel PS
Clin Cancer Res; 2002 Sep; 8(9):2894-901. PubMed ID: 12231534
[TBL] [Abstract][Full Text] [Related]
12. Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study.
Ursu R; Carpentier A; Metellus P; Lubrano V; Laigle-Donadey F; Capelle L; Guyotat J; Langlois O; Bauchet L; Desseaux K; Tibi A; Chinot O; Lambert J; Carpentier AF
Eur J Cancer; 2017 Mar; 73():30-37. PubMed ID: 28142059
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory effect of cytosine-phosphate-guanosine (CpG)-oligonucleotides in nonasthmatic chronic rhinosinusitis: an explant model.
Tan L; Rogers TJ; Hatzirodos N; Baker LM; Ooi E; Wormald PJ
Am J Rhinol Allergy; 2009; 23(2):123-9. PubMed ID: 19401034
[TBL] [Abstract][Full Text] [Related]
14. [Toll-like receptor 9 in cpG oligodeoxynucleotides-induced species-specific immune responses].
Li N; Fan XG; Tang SE; Zhu C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Oct; 30(5):533-5. PubMed ID: 16320582
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients.
Wang LF; Fokas E; Bieker M; Rose F; Rexin P; Zhu Y; Pagenstecher A; Engenhart-Cabillic R; An HX
Oncol Rep; 2008 Jan; 19(1):151-6. PubMed ID: 18097589
[TBL] [Abstract][Full Text] [Related]
16. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
[TBL] [Abstract][Full Text] [Related]
17. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
Merlo A; Calcaterra C; Mènard S; Balsari A
J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
[TBL] [Abstract][Full Text] [Related]
18. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
19. Expression of diagnostic neuronal markers and outcome in glioblastoma.
Donev K; Scheithauer BW; Rodriguez FJ; Jenkins S
Neuropathol Appl Neurobiol; 2010 Aug; 36(5):411-21. PubMed ID: 20298476
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma.
Carpentier A; Laigle-Donadey F; Zohar S; Capelle L; Behin A; Tibi A; Martin-Duverneuil N; Sanson M; Lacomblez L; Taillibert S; Puybasset L; Van Effenterre R; Delattre JY; Carpentier AF
Neuro Oncol; 2006 Jan; 8(1):60-6. PubMed ID: 16443949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
